These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 25251053)

  • 21. EpCAM-autoantibody levels in the course of disease of ovarian cancer patients.
    Heubner M; Errico D; Kasimir-Bauer S; Herlyn D; Kimmig R; Wimberger P
    Med Oncol; 2011 Jun; 28(2):626-30. PubMed ID: 20383668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EpCAM expression in esophageal cancer and its correlation with immunotherapy of solitomab.
    Yu L; Guo QM; Wang Y; Xu Y; Liu L; Zhang XT
    J Thorac Dis; 2021 Apr; 13(4):2404-2413. PubMed ID: 34012588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.
    Amann M; Brischwein K; Lutterbuese P; Parr L; Petersen L; Lorenczewski G; Krinner E; Bruckmeier S; Lippold S; Kischel R; Lutterbuese R; Kufer P; Baeuerle PA; Schlereth B
    Cancer Res; 2008 Jan; 68(1):143-51. PubMed ID: 18172306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The activity of γδ T cells against paediatric liver tumour cells and spheroids in cell culture.
    Hoh A; Dewerth A; Vogt F; Wenz J; Baeuerle PA; Warmann SW; Fuchs J; Armeanu-Ebinger S
    Liver Int; 2013 Jan; 33(1):127-36. PubMed ID: 23088518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes.
    Schmitt M; Schmitt A; Reinhardt P; Thess B; Manfras B; Lindhofer H; Riechelmann H; Wiesneth M; Gronau S
    Int J Oncol; 2004 Oct; 25(4):841-8. PubMed ID: 15375531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
    Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
    Schlereth B; Fichtner I; Lorenczewski G; Kleindienst P; Brischwein K; da Silva A; Kufer P; Lutterbuese R; Junghahn I; Kasimir-Bauer S; Wimberger P; Kimmig R; Baeuerle PA
    Cancer Res; 2005 Apr; 65(7):2882-9. PubMed ID: 15805290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).
    Riesenberg R; Buchner A; Pohla H; Lindhofer H
    J Histochem Cytochem; 2001 Jul; 49(7):911-7. PubMed ID: 11410615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM/CD3-bispecific BiTE antibody MT110 efficacy against IDO1
    Hong R; Zhou Y; Tian X; Wang L; Wu X
    Int Immunopharmacol; 2018 Jan; 54():118-124. PubMed ID: 29128855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
    Burges A; Wimberger P; Kümper C; Gorbounova V; Sommer H; Schmalfeldt B; Pfisterer J; Lichinitser M; Makhson A; Moiseyenko V; Lahr A; Schulze E; Jäger M; Ströhlein MA; Heiss MM; Gottwald T; Lindhofer H; Kimmig R
    Clin Cancer Res; 2007 Jul; 13(13):3899-905. PubMed ID: 17606723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells.
    Herrmann I; Baeuerle PA; Friedrich M; Murr A; Filusch S; Rüttinger D; Majdoub MW; Sharma S; Kufer P; Raum T; Münz M
    PLoS One; 2010 Oct; 5(10):e13474. PubMed ID: 20976159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
    Huang C; Li H; Feng Y; Li X; Zhang Z; Jiang C; Wang J; Yang C; Fu Y; Mu M; Zhao S; Wang Z; Kuang Y; Hou H; Wang Y; Guo W; Xu J; Yang H; Zhou L; Tong A; Guo G
    Theranostics; 2020; 10(23):10498-10512. PubMed ID: 32929362
    [No Abstract]   [Full Text] [Related]  

  • 34. Intrahepatically transplanted human cord blood cells reduce SW480 tumor growth in the presence of bispecific EpCAM/CD3 antibody.
    Wulf-Goldenberg A; Eckert K; Fichtner I
    Cytotherapy; 2011 Jan; 13(1):108-13. PubMed ID: 20839999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1.
    Kroesen BJ; Nieken J; Sleijfer DT; Molema G; de Vries EG; Groen HJ; Helfrich W; The TH; Mulder NH; de Leij L
    Cancer Immunol Immunother; 1997; 45(3-4):203-6. PubMed ID: 9435874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-α.
    Rossi EA; Rossi DL; Cardillo TM; Chang CH; Goldenberg DM
    Mol Cancer Ther; 2014 Oct; 13(10):2341-51. PubMed ID: 25053819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy.
    Mitra M; Kandalam M; Harilal A; Verma RS; Krishnan UM; Swaminathan S; Krishnakumar S
    Mol Vis; 2012; 18():290-308. PubMed ID: 22328825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model.
    Ren-Heidenreich L; Davol PA; Kouttab NM; Elfenbein GJ; Lum LG
    Cancer; 2004 Mar; 100(5):1095-103. PubMed ID: 14983507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro.
    Seeber A; Martowicz A; Spizzo G; Buratti T; Obrist P; Fong D; Gastl G; Untergasser G
    BMC Cancer; 2015 May; 15():372. PubMed ID: 25947366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.
    Riillo C; Polerà N; Di Martino MT; Juli G; Hokanson CA; Odineca T; Signorelli S; Grillone K; Ascrizzi S; Mancuso A; Staropoli N; Caparello B; Cerra M; Nisticò G; Tagliaferri P; Crea R; Caracciolo D; Tassone P
    J Transl Med; 2023 May; 21(1):301. PubMed ID: 37143061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.